Corvidia raises $26M, licenses cardio candidate

Corvidia Therapeutics (Boston, Mass.) raised $26 million in a series A round and licensed cardiovascular mAb COR-001 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Sofinnova Partners and Apple Tree Partners led the round.

Corvidia said it would conduct a Phase I/II trial of COR-001 to treat cardiovascular disease. AZ had studied the compound in a Phase I trial to treat a different indication, which Corvidia Co-Founder and CEO Michael Davidson declined to disclose. ...